The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
It was mentioned in a long ago post that Edelman had said that the Nanoco patenting strategy was to leave out a processing stage that made it difficult to apply the technology. This would not accord with patenting rules that you should describe the technology in such a way that a person skilled in the art can carry it out. This makes Edelman's statement a difficulty for Nanoco unless the statement was made after filing and that subsequent to filing Nanoco had improved the process i.e.the patented process produced QDs but they were not good enough for the TV application, but were subsequently improved to be good enough for TVs.
The difficulty for Samsung is that to overturn the patent they have to say that there was not sufficient information in the patent for one skilled in the art to carry out the invention. If they argue this, they are on the horns of a dilemma because they can no longer argue that their supplier's staff (skilled in the art) developed the missing process independently. If they do not argue this. they must have used Nanoco's secret process, presumably divulged under NDA and are liable for breach of the NDA.
We are all guessing so WhatdoIknow?
As gas domestic boilers are phased down by public policy, the proportion of H2 in the grid will rise or fall depending on the uptake speed of H2 in heavy road transport, rail and marine. Thus, using the H2 in the grid provides an excellent buffer. It enables green hydrogen production to ramp up with reduced risk until transport use takes over.
AbbVie Inc - US biopharmaceutical company - Partners with Frontier Medicines Corp to develop and commercialise "small molecule therapeutics" for hard to drug protein targets. "Under the multi-year collaboration, AbbVie and Frontier will utilize Frontier's proprietary chemoproteomics platform to identify small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets,"
Replies so far do not reflect the importance of IQGeVSEL 150 technology. Yes, this makes the chips cheaper to produce, but more importantly for profitability moving from 200 to 300 more than doubles the wafer area, so the same factory unit produces double the number of wafers i.e doubles production. The cost of new machines has held back profits at IQE and PI's on this board have questioned why are more machines not being ordered? Now we know that production can be doubled with the currently installed machinery. The Board must have known this was coming for a long time.
Next question is what are they planning to do with the surplus space at the Newport magafoundry?
Just had an email from The Green Room offering Edinburgh Genetics Antigen test (nasal/throat) 20 minutes for 39.99. anyone have info on this, or is it another own label? The web site says >5000 in stock.
Don't you mean that people who think that they can time the market are "special"
While patent cases revolve round what the patent claims and what the description states, I presume that e-discovery may relate to emails etc. These will be important for establishing wilful infringement and hence damages.
For Samsung to buy Nanoco and end the lawsuit must be tempting, but the incentive for insiders to buy a package of Nanoco shares and then agree a huge settlement may be higher. They could retire on a 100+ bagger with little risk.
I now think that Magabatteries to store surplus renewable electricity are not viable competition for hydrogen.
The reversed output from battery storage is still electricity, being sold into a market in mostly in surplus. To get a reasonable return on capital you need to discharge and recharge the battery every day, which brings you up against battery life. Even the vaunted "million mile battery" will only achieve 2,500 cycles, which is less than ten years of daily cycling.
Green hydrogen production, on the other hand, permanently removes surplus electrical output from the electricity market.
Thoughts?
The Abbot test was being used daily in the White House, but it seems that it was not accurate enough to prevent an outbreak.
TheLlancet article shows the ways in which swab false positives can occur:-
Technical problems including contamination during sampling (eg, a swab accidentally touches a contaminated glove or surface), contamination by PCR amplicons, contamination of reagents, sample cross-contamination, and cross-reactions with other viruses or genetic material could also be responsible for false-positive results.2
Not noted in the Lancet article, but positive for Avacta saliva tests is that these problems are far more likely where where multiple samples are taken in the same place and where the samples are sent for processing to a central lab where multiple samples are present. Self administered in isolation and smart phone reported POC saliva tests avoids these dangers.
About half the trades now are for more than £10k as compared to the usual PI trades in the low hundreds.
Sorry - Bruker not Brucker.
The Brucker paper is dated as "Modified" 28th September
There have been several valuations of Carclo advanced here, but they all seem to ignore the certainty(?) of a shortage of capacity in the medical plastics industry. If there are few qualified manufacturers, margins can be increased, even from current customers.
There is some misunderstanding in this discussion about what taking orders for new tooling means. Tooling refers to the moulds for producing parts. The customer pays for the tooling which is a very significant up from cost. Taking orders for new tooling does not mean Carclo orders more production machinery. It means that new customers have put down money for future production of their required parts. From memory, I think Carclo bought a tooling company a few years ago.
Perhaps a market with even greater promise would be washable liners for trainers. I hope that they are in touch with Nike.
So Thyssen-Krupp and Air Products line up against ITM and Linde, with both groups using electrolising technology. I take this as positive for electrolising. My concern with ITM has always been that there might be a better technology out there under the radar. I will sleep easier now.
Facemasks are very topical, but how do you count the number of washes a mask is subjected to. A far larger market is in scrubs gowns and ward bed curtains, which are washed regularly. Scrubs are washed after each session, but hospitals could save a great deal of money using anti-bacterial curtains and changing (costs nursing time) and washing (laundry cost) them less frequently.
Today's news that security guards have the highest risk of Covid-19 death may be positive for Thruvision. Obviously night watchmen are not in much danger but guards tasked with checking and frisking staff are very much at risk. Do firms just give up on theft to protect guards or do they install Thruvision machines and check from a distance without fear of legal consequences?